A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML
A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML
Active, not recruiting · NCT05199051 · Registry updated 2026-01-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 2 | 2026-01-05 | NCT05199051 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Acute Leukemia French Association | 5 |
| Astellas Pharma Inc | 43 |
| Centre Antoine Lacassagne | 24 |
| Pfizer | 431 |
12 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Centre Henri Becquerel | Rouen | France | 71 |
| Centre Hospitalier de Versailles | Versailles | France | 1 |
| Centre Hospitalier Universitaire de Nice | Nice | France | 6 |
| CHMS de Chambery | Chambéry | France | 1 |
| CHRU Nancy | Nancy | France | 31 |
| CHU Bordeaux | Bordeaux | France | 67 |
| CHU d'Amiens | Amiens | France | 13 |
| CHU d'Angers | Angers | France | 27 |
| Chu de Caen | Caen | France | 32 |
| CHU Limoges | Limoges | France | 42 |
| HIA Percy | Clamart | France | 3 |
| Hôpital Saint Louis | Paris | France | 21 |